3 81

Cited 32 times in

Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine

Authors
 Benjamin P. Sablan ; Dong Joon Kim ; William L. Heyward ; Hamid Namini ; JiHyun Lee ; Seong Gyu Hwang ; Sang Hoon Ahn ; Mong Cho ; Wan Cheng Chow ; Nina G. Barzaga 
Citation
 Vaccine, Vol.30(16) : 2689~2696, 2012 
Journal Title
 Vaccine 
ISSN
 0264-410X 
Issue Date
2012
Abstract
Adults 40 years of age and older have been shown to be hypo-responsive immunologically to the currently available hepatitis B virus (HBV) vaccines. Three intramuscular doses of a Toll-like receptor 9 agonist, 1018 immunostimulatory sequence (1018 ISS) adjuvant, combined with recombinant hepatitis B surface antigen (HBsAg) demonstrated faster, superior, and more durable seroprotection than three doses of a licensed comparator HBV vaccine (Engerix-B(®)). This investigational vaccine, HBsAg-1018 ISS, was well tolerated with a safety profile similar to the comparator vaccine. These results suggest that HBsAg-1018 may be more effective in this hypo-responsive population
URI
http://ir.ymlib.yonsei.ac.kr/handle/22282913/92001
DOI
10.1016/j.vaccine.2012.02.001
Appears in Collections:
1. 연구논문 > 1. College of Medicine > Dept. of Internal Medicine
Yonsei Authors
사서에게 알리기
  feedback
Link
 http://www.sciencedirect.com/science/article/pii/S0264410X1200165X
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse